We’re Coming Soon…

Selectin Therapeutics was formed to advance proprietary nanoparticle technologies developed at Memorial Sloan Kettering Cancer Center and Tel Aviv University designed to ferry drugs across the blood-brain barrier specifically at the site of disease by targeting the protein P-selectin on activated vascular endothelium.

With highly promising mouse efficacy data using different drug payloads and various preclinical cancer models showing improved survival and reduced toxicities versus current therapeutic approaches, our initial disease indication focus is on pediatric brain cancers – with the opportunity to expand to adult brain malignancies (both primary and metastatic) as well as to other focal brain disorders (e.g., multiple sclerosis, stroke, and focal epilepsy). We are currently raising our seed round of financing.